- Sustainability
- DE&I
- Pandemic
- Finance
- Legal
- Technology
- Regulatory
- Global
- Pricing
- Strategy
- R&D/Clinical Trials
- Opinion
- Executive Roundtable
- Sales & Marketing
- Executive Profiles
- Leadership
- Market Access
- Patient Engagement
- Supply Chain
- Industry Trends
Myeloma UK Announces New CEO
Myeloma UK announced that Rosemarie Finley has been appointed its new CEO. She is joining the company from the Epilepsy Society, where she was Acting Chief Executive and Chief Operating Officer.
Finley has held positions at Buckinghamshire Healthcare NHS Trust and has worked as a strategic advisor to several pharmaceutical companies, gaining over 30 years of management experience in the healthcare sector.
Myeloma UK is the primary organization in the UK dealing with myeloma, a type of blood cancer that affects plasma cells in the bone marrow. Its focus is on unlocking the potential for the development and delivery of new treatments, through primary research, strategic partnerships, education, and campaigning.
IMF Chief Medical Officer Discusses Global Initiatives to Improve Myeloma Treatment
August 20th 2024In an interview with Pharm Exec Associate Editor Don Tracy, Joseph Mikhael, chief medical officer, IMF, offers a glimpse at multiple initiatives that the IMF is working towards to improve myeloma treatment globally.
